UBS keeps AUD 135.00 target for Cochlear stock

Published on 10/17/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts set an average AUD 136.15 target on October 16, 2026. Cochlear stock costs EUR 80.70 on October 17, 2026, 51.40 percent below its 52-week high.

Analyst target and valuation

UBS maintained its Hold rating and set an AUD 135.00 target on October 15, 2026.
The average target from 16 analysts was AUD 136.15 on October 16, 2026.
Cochlear stock stood at EUR 80.70 at Tradegate on October 17, 2026 at 8:02 p.m. CEST, 51.40 percent below its 52-week high.
Cochlear's P/E ratio was 55.78 and its market capitalization was EUR 5.3 billion on October 17, 2026.

Cochlear, AU000000COH5, Illustration mit AI erstellt.

UBS maintained its Hold rating for Cochlear and set an AUD 135.00 price target on October 15, 2026, according to Markets Insider. Against the AUD 131.13 home-market price on October 16, 2026, that target was 2.95 percent higher. The euro quote stood at EUR 80.70 at Tradegate on October 17, 2026 at 8:02 p.m. CEST.

Average target stays above AUD 136

The wider analyst picture points to an average 12-month target of AUD 136.15 from 16 analysts on October 16, 2026. The estimate was 3.83 percent above the AUD 131.13 Cochlear price, while the published range ran from AUD 110.00 to AUD 165.00, according to Investing.com.

Stock remains below its yearly high

The euro quotation sits EUR 85.34 below the 52-week high of EUR 166.04 and EUR 25.81 above the 52-week low of EUR 54.89. Tradegate showed a bid of EUR 80.26 and an ask of EUR 81.07 at 8:02 p.m. CEST on October 17, 2026. The displayed market capitalization was EUR 5.32 billion, while the price-to-earnings ratio was 55.78.

Valuation and peer comparison

Cochlear's latest reported quarter ended June 30, 2026, with revenue of AUD 1.16 billion and a GAAP net loss of AUD 14.20 million, compared with revenue of AUD 1.19 billion and net profit of AUD 183.80 million in the year-earlier quarter, according to Markets Insider. The company identifies financial results and key dates on its investor-relations page.

Comparison with peers

Cochlear: P/E 55.78, market capitalization EUR 5.3 billion
ResMed (ASX, AUD): plus 2.26 percent, P/E 22.98, market capitalization AUD 48.3 billion
Sonova (SIX, CHF): plus 1.39 percent, P/E 38.50, market capitalization CHF 16.5 billion

Price position for investors

Cochlear combines a target range above its latest home-market price with a euro quotation well below its 52-week high. The figures put valuation and the next company update ahead of short-term price direction.

The stock stood at EUR 80.70 at Tradegate on October 17, 2026 at 8:02 p.m. CEST, with a 52-week range of EUR 54.89 to EUR 166.04.